NZ244458A - Metal alkoxides of taxane derivatives - Google Patents
Metal alkoxides of taxane derivativesInfo
- Publication number
- NZ244458A NZ244458A NZ244458A NZ24445892A NZ244458A NZ 244458 A NZ244458 A NZ 244458A NZ 244458 A NZ244458 A NZ 244458A NZ 24445892 A NZ24445892 A NZ 24445892A NZ 244458 A NZ244458 A NZ 244458A
- Authority
- NZ
- New Zealand
- Prior art keywords
- solution
- taxol
- mixture
- ethyl acetate
- thf
- Prior art date
Links
- 150000004703 alkoxides Chemical class 0.000 title claims abstract description 27
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 27
- 239000002184 metal Substances 0.000 title claims abstract description 27
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 16
- 125000006239 protecting group Chemical group 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 141
- 239000000203 mixture Substances 0.000 claims description 78
- 229930012538 Paclitaxel Natural products 0.000 claims description 74
- 229960001592 paclitaxel Drugs 0.000 claims description 72
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 34
- 229920006395 saturated elastomer Polymers 0.000 claims description 32
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 31
- 238000001704 evaporation Methods 0.000 claims description 30
- 230000008020 evaporation Effects 0.000 claims description 30
- -1 1-ethoxyethyl Chemical group 0.000 claims description 29
- 238000003818 flash chromatography Methods 0.000 claims description 18
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 101100108327 Escherichia coli (strain K12) melA gene Proteins 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 9
- 229910052744 lithium Inorganic materials 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 101150041968 CDC13 gene Proteins 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000005106 triarylsilyl group Chemical group 0.000 claims 1
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 23
- 150000004200 baccatin III derivatives Chemical class 0.000 abstract description 6
- 229910052723 transition metal Inorganic materials 0.000 abstract description 2
- 150000003624 transition metals Chemical class 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 110
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 90
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 57
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 55
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 49
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 30
- 229930014667 baccatin III Natural products 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 23
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229940063683 taxotere Drugs 0.000 description 7
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 150000002902 organometallic compounds Chemical class 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000006242 amine protecting group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 150000004579 taxol derivatives Chemical class 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical group [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SKJSIVQEPKBFTJ-HUWILPJBSA-N taxusin Chemical compound C1[C@@H](C2(C)C)C[C@H](OC(C)=O)C(C)=C2[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@]2(C)CC[C@H](OC(=O)C)C(=C)[C@@H]12 SKJSIVQEPKBFTJ-HUWILPJBSA-N 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- 229930182986 10-Deacetyltaxol Natural products 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LSKNLLKWWYCSLU-UHFFFAOYSA-N 3-(1-ethoxyethoxy)-2-phenylazetidine Chemical compound CCOC(C)OC1CNC1C1=CC=CC=C1 LSKNLLKWWYCSLU-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FLAKGKCBSLMHQU-UHFFFAOYSA-N CC[Mg] Chemical group CC[Mg] FLAKGKCBSLMHQU-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000005104 aryl silyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000006364 carbonyl oxy methylene group Chemical group [H]C([H])([*:2])OC([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- PKMBLJNMKINMSK-UHFFFAOYSA-N magnesium;azanide Chemical group [NH2-].[NH2-].[Mg+2] PKMBLJNMKINMSK-UHFFFAOYSA-N 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005911 methyl carbonate group Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 150000002901 organomagnesium compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- AWQUYUAEGSCHBU-UHFFFAOYSA-N tert-butyl n-chlorocarbamate Chemical compound CC(C)(C)OC(=O)NCl AWQUYUAEGSCHBU-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Glass Compositions (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Saccharide Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
A metal alkoxide having the following formula: <IMAGE> (1) wherein T1 is hydrogen or a hydroxy protecting group, Z is -OT2, or -OCOCH3, T2 is hydrogen or a hydroxy protecting group, and M is selected from the group comprising Group IA, IIA and transition metals are useful in the preparation of biologically active derivatives of baccatin III and 10-deacetyl baccatin III.
Description
<div class="application article clearfix" id="description">
<p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number £44458 <br><br>
2 4 4 4 5 8 <br><br>
Priority Date(s): .2,3*33^,.?;f+\^.. <br><br>
It <br><br>
No.: Date: <br><br>
Complete L'.on Filsd: <br><br>
Class: .conoid j* <br><br>
Publication Date: <br><br>
P.O. Journal, No: ....... /3W., <br><br>
NEW ZEALAND <br><br>
PATENTS ACT, 1953 <br><br>
COMPLETE SPECIFICATION <br><br>
METAL ALKOXIDES <br><br>
We, FLORIDA STATE UNIVERSITY, a corporation of the State of Florida, United States of America, of 2035 East Paul Dirac Drive, Tallahassee, Florida 32310, United States of America hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- <br><br>
- 1 - <br><br>
(followed by page la) <br><br>
244 458 <br><br>
- la - <br><br>
BACKGROUND OF THE INVENTION <br><br>
The present invention is directed to novel metal alkoxides useful in the preparation of derivatives of baccatin III and 10-deacetyl baccatin III such as taxol, 10 taxotere and other taxane derivatives which have biological activity. <br><br>
The taxane family of terpenes, of which taxol is a member, has attracted considerable interest in both the biological and chemical arts. Taxol is a promising cancer 15 cheraotherapeutic agent with a broad spectrum of antileukemic and tumor-inhibiting activity. Taxol has the following structure: <br><br>
OAc <br><br>
CfiHgCONH O . „ .. <br><br>
i u ;' 0H <br><br>
/V*J' v s / \ --**■ n C6H^ 1 ommifls <br><br>
CI) <br><br>
OH <br><br>
\ / "<11116/* 7 \ <br><br>
OH i H ^r\ <br><br>
s OAc\ --0 OCOCgHg 30 <br><br>
Because of this promising activity, taxol is currently 20 undergoing clinical trials in both France and the United States. <br><br>
The supply of taxol for these clinical trials is presently being provided by the bark from Taxus brevifolia <br><br>
12 APR 1994 <br><br>
2 4 4 4 5 <br><br>
(Western Yew). However, taxol is found only in minute quantities in the bark of these slow growing evergreens, causing considerable concern that the limited supply of taxol will not meet the demand. Consequently, chemists in 5 recent years have expended their energies in trying to find a viable synthetic route for the preparation of taxols. So Ear, the results have not been entirely satisfactory. <br><br>
One synthetic route that has been proposed is directed to the synthesis of the tetracyclic taxane nucleus 10 from commodity chemicals. A synthesis of the taxol congener taxusin has been reported by Holton, et al. in JACS 110. 6558 (1988). Despite the progress made in this approach, the final total synthesis of taxol is, nevertheless, likely to be a multi-step, tedious, and 15 costly process. <br><br>
An alternate approach to the preparation of taxol has been described by Greene, et al. in JACS 110, 5917 ( 1988), and involves the use of a congener of taxol, 10-deacetyl baccatin III which has the structure of formula 20 II shown below: <br><br>
HOtlMHI <br><br>
Cii) <br><br>
10-deacetyl baccatin III is more readily available than taxol since it can be obtained from the needles of Taxus baccata. According to the method of Greene et al., 25 10-deacetyl baccatin III is converted to taxol by <br><br>
# <br><br>
3 <br><br>
attachment of the C-10 acetyl group and by attachment of the C-13 B-amido ester side chain through the esterification of the C-13 alcohol with a B-amido carboxylic acid unit. Although this approach requires 5 relatively few steps, the synthesis of the B-amido carboxylic acid unit is a multi-step process which proceeds in low yield, and the coupling reaction is tedious and also proceeds in low yield. However, this coupling reaction is a key step which is required in every contemplated 10 synthesis of taxol or biologically active derivative of taxol, since it has been shown by Wani, et al. in JACS 93. 2325 (1971) that the presence of the B-amido ester side chain at C13 is required for anti-tumor activity. <br><br>
More recently, it has been reported in Colin et 15 al. U.S. Patent No. 4,814,470 that taxol derivatives of the formula III below, have an activity significantly greater than that of taxol (I). <br><br>
R' represents hydrogen or acetyl and one of R*' and R''' 20 represents hydroxy and the other represents tert-butoxy-carbonylamino and their stereoisomeric forms, and mixtures thereof. <br><br>
According to Colin et al., U.S. Patent 4,418,470, the products of general formula (III) are obtained by the <br><br>
2 4 4 4 5 <br><br>
4 <br><br>
action of the sodium salt of tert-butyl N-chlorocarbamate on a product of general formula: <br><br>
J^l O Q OCOOCH2CI3 <br><br>
co-o <br><br>
J <br><br>
C0Hs in which R' denotes an acetyl or 2,2,2-trichloroethoxy-5 carbonyl radical, followed by the replacement of the <br><br>
2,2,2-trichloroethoxycarbonyl group or groups by hydrogen. It is reported by Denis et al. in U.S. Patent No. 4,924,011, however, that this process leads to a mixture of isomers which has to be separated and, as a result, not all 10 the baccatin III or 10-deactylbaccatin III employed for the preparation of the product of general formula (IV) can be converted to a product of general formula (III). <br><br>
In an effort to improve upon the Colin et al. process, Denis et al. disclose a different process for 15 preparing derivatives of baccatin III or of 10-deactylbaccatin III of general formula <br><br>
Civ) <br><br>
OH ; H OCOCgHg <br><br>
OCOCH- <br><br>
9 / / £ £ <br><br>
L \ 3 <br><br>
in which R' denotes hydrogen or acetyl wherein an acid of general formula: <br><br>
o—R, <br><br>
C vi) <br><br>
Cch3)3coconhv/ cooh <br><br>
in which R-^ is a hydroxy-protecting group, is condensed with a taxane derivative of general formula: <br><br>
ho -- <br><br>
OCOCH, <br><br>
OCOCgHg <br><br>
(VII) <br><br>
in which R2 is an acetyl hydroxy-protecting group and R3 is a hydroxy-protecting group, and the protecting groups R^, R3 and, where appropriate, R2 are then replaced by 10 hydrogen. However, this method employs relatively harsh conditions, proceeds with poor conversion, and provides less than optimal yields. <br><br>
A major difficulty remaining in the synthesis of taxol and other potential anti-tumor agents is the lack of 15 baccatin III and 10-deacetyl baccatin III derivatives which have been activated at the C-13 oxygen. Development of such derivatives would permit attachment of the B-amido ester side chain in high yield and thus, facilitate the synthesis of taxol as well as related anti-tumor agents 20 having a modified set of nuclear substituents or a modified C-13 side chain. <br><br>
•>' /' ■ -ft <br><br>
■ "7 ; 'T <br><br>
6 <br><br>
Another major difficulty encountered in the synthesis of taxol is that known processes for the attachment of the B-amido ester side chain at C-13 are generally not sufficiently diastereoselective. Therefore 5 the side chain precursor must be prepared in optically active form to obtain the desired diastereomer during attachment. <br><br>
SUMMARY OF THE INVENTION <br><br>
Among the objects of the present invention, 10 therefore, is the provision of activated baccatin III and 10-deacetyl baccatin III derivatives which permit attachment of the B-amido ester side chain in high yield, the provision of such derivatives which permit the use of a racemic mixture of side chain precursor, eliminating the 15 need for the expensive, time-consuming process of separating the precursor into its respective isomeric forms, and the provision of such derivatives which permit the preparation of taxanes having greater variety in the side-chain. <br><br>
20 Briefly, therefore, the present invention is directed to a metal alkoxide having the formula: <br><br>
MOimiiii ot, <br><br>
(1) <br><br>
wherein T^ is hydrogen or a hydroxy protecting group, Z is -OT2, or -OCOCH3, T2 is hydrogen or a hydroxy <br><br>
25 protecting group, and M is a metal, preferably, Li, Mg, Na, K or Ti. <br><br>
2 4 4 4 5 8 <br><br>
7 <br><br>
Other objects and features of this invention will be in part apparent and in part pointed out hereinafter. <br><br>
DETAILED DESCRIPTION <br><br>
Metal alkoxides (1) are activated derivatives of 5 baccatin III and/or 10-deacetyl baccatin III and have particular utility in a process for the preparation of taxol, taxotere and other biologically active taxane derivatives. In accordance with the present invention, metal alkoxides (1) are reacted with G-lactam (2) to form a 10 G-amido ester intermediate. The intermediate is then converted to a biologically active taxane derivative. B-lactam (2) has the general formula: <br><br>
* <br><br>
'— <br><br>
1 2 4 3 <br><br>
j <br><br>
C2) <br><br>
^3 *2 <br><br>
wherein <br><br>
15 Ri is -ORg, -SR7, or -NRgRg,* <br><br>
R2 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; <br><br>
R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or acyl, provided, 20 however, that R3 and R4 are not both acyl; <br><br>
R5 is —COR^g, -COOR^o, —COSR^g, —CONRgR-^g, <br><br>
-SO2R11t ~P0Ri2Ri3; <br><br>
R6 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxy protecting group; <br><br>
25 R7 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, <br><br>
or sulfhydryl protecting group; <br><br>
8 <br><br>
Rg is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; <br><br>
Rg is an amino protecting group; <br><br>
R10 is alkyl, alkenyl, alkynyl, aryl, or 5 heteroaryl; <br><br>
R^2. alkyl, alkenyl, alkynyl, aryl, heteroaryl, -ORiq/ or —NRgR^^; <br><br>
R22 an<3 Ri3 are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, -OR10, or -NRgR14; and 10 R14 is hydrogen, alkyl, alkenyl, alkynyl, aryl, <br><br>
or heteroaryl. <br><br>
In accordance with the present invention, R5 of 13-lactam (2) is preferably -COR^q with Rjq with R^q being aryl, p-substituted phenyl, or lower alkoxy, and most 15 preferably, phenyl, methoxy, ethoxy, tert-butoxy ("tBuO"; (CH3)3CO-) or wherein X is CI, Br, F, CH30-, or N02-. Preferably R2 and R4 are hydrogen or lower alkyl. R3 is preferably aryl, 20 most preferably, naphthyl, phenyl, <br><br>
f .? <br><br>
9 <br><br>
'OMe <br><br>
Ph or wherein X is as previously defined, Me is methyl and Ph is phenyl. Preferably, is selected from -ORg, -SRy or 5 -NRgRg wherein Rg, R? and Rg, are hydroxy, sulfhydryl, and amine protecting groups, respectively, and Rg is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl. Most preferably, R^ is -ORg wherein Rg is triethylsilyl ("TES"), 1-ethoxyethyl ("EE") or 2,2,2-trichloroethoxymethyl. 10 The 13-lactam alkyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include methyl, ethyl, 15 propyl, isopropyl, butyl, isobutyl, tert-butyl, aryl, hexyl, and the like. <br><br>
the various substituents defined hereinabove are preferably lower alkenyl containing from two to six carbon atoms in 20 the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, aryl, hexenyl, and the like. <br><br>
25 the various substituents defined hereinabove are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be <br><br>
The 13-lactam alkenyl groups, either alone or with <br><br>
The 13-lactam alkynyl groups, either alone or with <br><br>
^ f / / vT O <br><br>
/ Li, I', is. " ; rl <br><br>
10 <br><br>
straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, aryl, hexynyl, and the like. <br><br>
The 13-lactam aryl moieties described, either alone or with various substituents, contain from 6 to 15 5 carbon atoms and include phenyl, a-naphthyl or fi-naphthyl, etc. Substituents include alkanoxy, protected hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino, amido, etc. Phenyl is the more preferred aryl. <br><br>
As noted above, R^ of 13-lactam (2) may be -ORg 10 with Rg being alkyl, acyl, ethoxyethyl ("EE"), <br><br>
triethylsilyl ("TES"), 2,2,2-trichloroethoxymethy1, or other hydroxyl protecting group such as acetals and ethers, i.e., methoxymethyl ("MOM"), benzyloxymethyl; esters, such as acetates; carbonates, such as methyl carbonates; and 15 alkyl and aryl silyl such as triethylsilyl, trimethylsilyl, dimethyl-t-butylsilyl, dimethylarylsilyl, dimethyl-heteroarylsilyl, and triisopropylsilyl, and the like. A variety of protecting groups for the hydroxyl group and the synthesis thereof may be found in "Protective Groups in 20 Organic Synthesis" by T. W. Greene, John Wiley and Sons, 1981. The hydroxyl protecting group selected should be easily removed under conditions that are sufficiently mild, e.g., in 48% HF, acetonitrile, pyridine, or 0.5% HCl/water/ethanol, and/or zinc, acetic acid so as not to 25 disturb the ester linkage or other substituents of the taxol intermediate. <br><br>
Also as noted previously, Ry may be a sulfhydryl protecting group and Rg may be an amine protecting group. Sulfhydryl protecting groups include hemithioacetals such 30 as 1-ethoxyethyl and methoxymethyl, thioesters, or thiocarbonates. Amine protecting groups include carbamates, for example, 2,2,2-trichloroethylcarbamate or tertbutylcarbamate. A variety of sulfhydryl and amine protecting groups may be found in the above-identified text 35 by T. W. Greene. <br><br>
m 4 H o <br><br>
11 <br><br>
The 13-lactams (2) can be prepared from readily available materials, as is illustrated in schemes A and B below: <br><br>
Scheme A <br><br>
ci <br><br>
Ar OEE <br><br>
ch3o, <br><br>
OCH, <br><br>
Vf° <br><br>
Ar OEE <br><br>
cd <br><br>
Ar OAc b <br><br>
HW° <br><br>
^ \ <br><br>
Ar OAc <br><br>
Scheme B <br><br>
A <br><br>
TESO OEt <br><br>
ArC HO <br><br>
H. <br><br>
rf <br><br>
^—\ Ar 'OTES <br><br>
Ar OTES <br><br>
reagents: (a) triethylamine, CH2C12, 25°C, 18h; (b) 4 equiv eerie ammonium nitrate, CH3CN, -10°C, 10 min; (c) KOH, THF, H20, 0°C, 30 min; (d) ethyl vinyl ether, THF, toluene sulfonic acid (cat.), 0°C, 1.5h; (e) n-butyllithium, ether, 15 -78°C, 10 min; benzoyl chloride, -78°C, lh; (f) lithium <br><br>
4 <br><br>
12 <br><br>
diisopropyl amide, THF -78°C to -50°C; (g) lithium hexamethyldisilazide, THF -78°C to 0°C; (h) THF, -78°C to 25 °C, 12h. <br><br>
The starting materials are readily available. In 5 scheme A, a-Acyloxy acetyl chloride is prepared from glycolic acid, and, in the presence of a tertiary amine, it cyclocondenses with imines prepared from aldehydes and p-methoxyaniline to give l-p-methoxyphenyl-3-acyloxy-4-arylazetidin-2-ones. The p-methoxyphenyl group can be 10 readily removed through oxidation with eerie ammonium nitrate, and the acyloxy group can be hydrolyzed under standard conditions familiar to those experienced in the art to provide 3-hydroxy-4-arylazetidin-2-ones. The 3-hydroxyl group is protected with 1-ethoxyethyl, but may 15 be protected with variety of standard protecting groups such as the triethylsilyl group or other trialkyl (or aryl) silyl groups. In Scheme B, ethyl-a-triethylsilyloxyacetate is readily prepared from glycolic acid. <br><br>
The racemic fl-lactams may be resolved into the 20 pure enantiomers prior to protection by recrystallization of the corresponding 2-methoxy-2-(trifluoromethyl) phenylacetic esters. However, the reaction described hereinbelow in which the fi-amido ester side chain is attached has the advantage of being highly diastereo-25 selective, thus permitting the use of a racemic mixture of side chain precursor. <br><br>
The 3-(l-ethoxyethoxy)-4-phenylazetidin~2-one of Scheme A and the 3-(l-triethylsilyl)-4-phenylazetidin-2-one of Scheme B can be converted to B-lactam (2), by treatment 30 with a base, preferably n-butyllithium, and an acyl chloride, sulfonyl chloride, phosphinyl chloride, phosphoryl chloride or an alkyl chloroformate at -78°C or less. <br><br>
Preferably, the metal alkoxides are prepared by 35 reacting an alcohol having two to four rings of the taxane <br><br>
2 4 4 4 <br><br>
13 <br><br>
nucleus and a C-13 hydroxyl group with an organometallic compound in a suitable solvent. Most preferably, the alcohol is a protected baccatin III, in particular, 7-0-triethylsilyl baccatin III (which can be obtained as 5 described by Greene, et al. in JACS 110. 5917 (1988) or by other routes) or 7,lO-bis-O-triethylsilyl baccatin III. <br><br>
As reported in Greene et al., 10-deacetyl baccatin III is converted to 7-O-triethylsilyl-lO-deacetyl baccatin III according to the following reaction scheme: <br><br>
OCOCgHg <br><br>
(3) (4a) <br><br>
Under what is reported to be carefully optimized conditions, 10-deacetyl baccatin III is reacted with 20 equivalents of (C2H5)3SiCl at 23°C under an argon 15 atmosphere for 20 hours in the presence of 50 ml of pyridine/mmol of 10-deacetyl baccatin III to provide 7-triethylsilyl-10-deacetyl baccatin III (4a) as a reaction product in 84-86% yield after purification. <br><br>
The reaction product (4a) is then acetylated with 20 5 equivalents of CH3COCI and 25 mL of pyridine/mmol of 4a at 0 °C under an argon atmosphere for 48 hours to provide 86% yield of 7-O-triethylsilyl baccatin III (4b) as reported by Greene, et al. in JACS 110. 5917 at 5918 (1988). <br><br>
Alternatively, 7-triethylsilyl-10-deacetyl 25 baccatin III (4a) can be protected at C-10 oxygen with an <br><br>
24 4 4 5 <br><br>
14 <br><br>
acid labile hydroxyl protecting group. For example, treatment of (4a) with n-butyllithium in THF followed by triethylsilyl chloride (1.1 mol equiv.) at 0°C gives 7,10-bis-0-triethylsilyl baccatin III (4c) in 95% yield. Also, (4a) can be converted to 7-0-treithylsilyl-10-(l-ethoxyethyl) baccatin III (4d) in 90% yield by treatment with excess ethyl vinyl ether and a catalytic amount of methane sulfonic acid. These preparations are illustrated in the reaction scheme below. <br><br>
ococh3 <br><br>
OSiCC2H3)3 <br><br>
C4b) <br><br>
CjHJN <br><br>
OCOCH3 <br><br>
ococghg <br><br>
OSi(Cj Hg)3 <br><br>
n-BuLi <br><br>
OSlCC2Hg)3 <br><br>
4a <br><br>
HOHMiti <br><br>
(C2H5)3SiCl <br><br>
(4c) <br><br>
OCOCH3 <br><br>
OCOCgHg <br><br>
OEE <br><br>
0SiCC2H5)3 <br><br>
CCAT)CH3S03H <br><br>
HO'iinn <br><br>
(4d) <br><br>
OCOCHg <br><br>
OCOCgHg <br><br>
2 4 4 4 5 <br><br>
15 <br><br>
The 7-0-triethylsilyl baccatin III derivatives (4b, 4c or 4d) are reacted with an organometallic compound such as n-butyllithium in a solvent such as tetrahydrofuran (THF), to form the metal alkoxide 13-0-lithium-7-0-tri-5 ethylsilyl baccatin III derivative (5b, 5c or 5d) as shown in the following reaction scheme: <br><br>
z <br><br>
THF <br><br>
CH- <br><br>
CHaCHjCHjCHa + Lio-yj <br><br>
CH3 OSiCC2H5)3 <br><br>
OCOCqHJ <br><br>
(22b) Z = C22c) Z = C22d) Z = <br><br>
-OCOCH3 <br><br>
-OSiCCjHsDg <br><br>
-OEE <br><br>
10 As shown in the following reaction scheme, the <br><br>
13-0-lithium-7-0-triethylsilyl baccatin III derivative (5b, 5c, or 5d) reacts with 13-lactam (2) to provide an intermediate (6b, 6c, or 6d) in which the C-7 and C-2' hydroxyl groups are protected with a triethylsilyl group. <br><br>
15 The triethylsilyl and ethoxyethyl groups are then hydrolyzed under mild conditions so as not to disturb the ester linkage or the taxane substituents. <br><br>
16 <br><br>
2 4 4 4 <br><br>
z z <br><br>
ot. <br><br>
5 b-d <br><br>
(2) <br><br>
6 b-d b, Z = -OCOCH3 c/ Z = -OSi(C2Hj)j d, Z = -OEE <br><br>
5 <br><br>
wherein is a hydroxy protecting group; M is a metal; Ph is phenyl; Ac is acetyl; and to R5 are as previously defined. <br><br>
10 Group IA, IIA, IIIA, lanthanide or actinide element or a transition, Group IIIA, IVA, VA or VIA metal. Preferably, it is a Group IA, IIA or transition metal, and most preferably, it is lithium, magnesium, sodium, potassium or titanium. <br><br>
15 Both the conversion of the alcohol to the metal alkoxide and the ultimate synthesis of the taxane derivative can take place in the same reaction vessel. Preferably, the B-lactam is added to the reaction vessel after formation therein of the metal alkoxide. <br><br>
20 The organometallic compound n-butyllithium is preferably used to convert baccatin III or 10-deacetyl baccatin III to the corresponding metal alkoxide, but other sources of metallic substituent such as lithium diisopropyl amide, other lithium or magnesium amides, ethylmagnesium <br><br>
Metal substituent, M, of metal alkoxide (3) is a <br><br>
17 <br><br>
bromide, methylmagnesium bromide, other organolithium compounds, other organomagnesium compounds, organosodium, organot itanium or organopotassium may also be used. Organometallic compounds are readily available, or may be 5 prepared by available methods including reduction of organic halides with metal. For example, butyl bromide can be reacted with lithium metal in diethyl ether to give a solution of n-butyllithium in the following manner: <br><br>
-10°C <br><br>
CH3CH2CH2CH2Br + 2 Li *> CH3CH2CH2CH2Li + LiBr <br><br>
ECjO <br><br>
10 Although THF is the preferred solvent for the reaction mixture, other ethereal solvents, such as dimethoxyethane, or aromatic solvents may also be suitable. Certain solvents, including some halogenated solvents and some straight-chain hydrocarbons in which the 15 reactants are too poorly soluble, are not suitable. Other solvents are not appropriate for other reasons. For example, esters are not appropriate for use with certain organometallic compounds such as n-butyllithium due to incompatibility therewith. <br><br>
20 Although the reaction scheme disclosed herein is ideally directed to the synthesis of taxol, taxotere, and other taxane derivatives exemplified herein, it can be used with modifications in either the 13-lactam or the tetracyclic metal alkoxide to produce other compounds. 25 Thus, the 13-lactam ana the tetracyclic metal alkoxide can be derived from natural or unnatural sources, to prepare other synthetic taxols, taxol derivatives, 10-deacetyl-taxols, and the enantiomers and diastereomers thereof contemplated within the present invention. 30 The process of the invention also has the important advantage of being highly diastereoselective. Therefore racemic mixtures of the side chain precursors may <br><br>
24 4 4! <br><br>
18 <br><br>
be used. Substantial cost savings may be realized because there is no need to resolve racemic G-lactams into their pure enantiomers. Additional cost savings may be realized because less side chain precursor, e.g., 60-70% less, is 5 required relative to prior processes. <br><br>
The following examples illustrate the invention. <br><br>
EXAMPLE 1 <br><br>
Preparation of 2•-ethoxyethyl-7-triethylsilyl taxol, and subsequently taxol, from racemic 13-lactam: <br><br>
10 To a solution of 7-triethylsilyl baccatin III <br><br>
(20mg, 0.028 mmol) in 1 ml of THF at -78°C was added dropwise 0.17 ml of a 0.164M solution of nBuLi in hexane. After 30 min at -78°C, a solution of cis-l-benzoyl-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one (47.5 mg, 0.14 15 mmol) in 1 ml of THF was added dropwise to the mixture. The solution was allowed to slowly warm (over 1.5 h) to 0°C and was then stirred at 0°C for 1 h and 1 ml of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 20 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by flash chromatography to give 23 mg (80%) of (2*R, 3'S)-2'-ethoxyethyl-7-triethylsilyl taxol and 3.5 mg (13%) of 2',3'-epi(2'S, 3'R)-2'-ethoxyethy1-7-triethylsilyl taxol. 25 A 5 mg sample of (2'R, 3'S)-2'-ethoxyethyl- <br><br>
7-triethylsilyl taxol was dissolved in 2 ml of ethanol, and 0.5 ml of 0.5% aqueous HC1 solution was added. The mixture was stirred at 0°C for 30 h and diluted with 50 ml of ethyl acetate. The solution was extracted with 20 ml of 30 saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography to provide 4.5 mg (ca.90%) taxol, <br><br>
2 4 4 4 <br><br>
19 <br><br>
which was identical with an authentic sample in all respects. <br><br>
A 5 mg sample of 2',3'-epi(2'S,3'R)-2'-ethoxy-ethyl-7-triethylsilyl taxol was dissolved in 2 ml of 5 ethanol and 0.5 ml of 0.5% aqueous HC1 solution was added. The mixture was stirred at 0°C for 30 h and diluted with 50 ml of ethyl acetate. The solution was extracted with 20 ml of saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated. The residue was 10 purified by flash chromatography to provide 4.5 mg (ca.90%) of 2',3'-epitaxol. <br><br>
EXAMPLE 2 <br><br>
Preparation of 27-(bis)triethylsilyl taxol, and subsequently taxol, from racemic 13-lactam: <br><br>
15 To a solution of 7-triethylsilyl baccatin III <br><br>
(lOOmg, 0.143 mmol) in 1 ml of THF at -45°C was added dropwise 0.087 ml of a 1.63M solution of nBuLi in hexane. After 1 h at -45°C, a solution of cis-l-benzoyl-3-triethylsilyloxy)-4-phenylazetidin-2-one (274 mg, 0.715 20 mmol) in 1 ml of THF was added dropwise to the mixture. <br><br>
The solution was allowed to warm to 0°C and held at 0°C for . 1 h. One ml of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the 25 organic layer gave a residue which was purified by flash chromatography followed by recrystallization to give 131 mg (85%) of (2'R, 3'S)-2',7-(bis)triethylsilyl taxol and 15 mg (10%) of 2',3'-epi(2'S,3'R)-2',7-(bis)triethylsilyl taxol. <br><br>
To a solution of 121.3 mg (0.112 mmol) of (2'R, 30 3'S)-2',7-(bis)triethylsilyl taxol in 6 ml of acetonitrile and 0.3 ml of pyridine at 0°C was added 0.9 ml of 48% aqueous HF. The mixture was stirred at 0°C for 8 h, then at 25°C for 6 h. The mixture was partitioned between <br><br>
24 4 4 <br><br>
20 <br><br>
saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 113 mg of material which was purified by flash chromatography and recrystallization to give 94 mg (98%) taxol, which was 5 identical with an authentic sample in all respects. <br><br>
To a solution of 5 mg of (2'R, 3 'S)-2' , 7-(bis) triethylsilyl taxol in 0.5 ml of acetonitrile and 0.03 ml of pyridine at 0°C was added 0.09 ml of 48% aqueous HF. The mixture was stirred at 0°C for 8 h, then at 25°C for 6 10 h. The mixture was partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 5 mg of material which was purified by flash chromatography and recrystallization to give 4.6 mg (ca. 95%) of 2',3'-epitaxol. <br><br>
24 4 4 5 <br><br>
21 <br><br>
EXAMPLE 3 <br><br>
Preparation of taxotere. <br><br>
To a solution of 7,10-bis-triethylsilyl baccatin III (200 mg, 0.248 mmol)) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 5C, a solution of cis-1-(tert-butoxycarbonyl)-3-triethylsilyloxy-4-phenylazetidin-2-one (467 mg, 1.24 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 280 mg of crude 21,7,10-tris-triethylsilyl taxotere. <br><br>
« <br><br>
To a solution of 280 mg of the crude product obtained from the previous reaction in 12 mL of acetonitrile and 0.6 mL of pyridine at 0 °C was added 1.8 mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 215 mg of material which was purified by flash chromatography to give 190 mg (95%) of taxotere, which was recrystallized from methanol/water. All analytical and spectral data were identical with that reported for taxotere in U. S. Patent 4,814,470. <br><br>
EXAMPLE 4 <br><br>
OAc o <br><br>
24 4458 <br><br>
22 <br><br>
wherein Np2 is <br><br>
Preparation of 3 '-desphenyl-3'-(2-naphthyl) taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-triethylsilyloxy-4-(2-naphthyl)azetidin-2-one (620 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 320 mg of, a mixture containing (2'R,3'S)-2',7-(bis)triethylsilyl-3'-desphenyl-3'-(2-naphthyl) taxol and a small amount of the (2'S/3'R) isomer. <br><br>
To a solution of 320 mg (0.283 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C was added 2.8 mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 255 mg of material which was purified by flash chromatogr'|^hKv^.oN give <br><br>
' * o\\ <br><br>
24 4 4 5 8 <br><br>
23 <br><br>
166 mg (64%) of 3'-desphenyl-3'-(2-naphthyl) taxol, which was recrystallized from methanol/water. <br><br>
m.p. 164-165 °C;[a]25Na-52.6° (c 0.005, CHC13). <br><br>
1H NMR (CDCI3, 300 MHz) S 8.14 (d, J = 7.3 Hz, 2H; benzoate ortho) , 7.96 (m, 1H, aromatic), 7.90 (m, 1H, aromatic), 7.85 (m, 2H, aromatic), 7.76 (m, 2H, aromatic), 7.60 (m, 3H, aromatic), 7.52 (m, 4H, aromatic), 7.41 (m, 2H, aromatic), 7.01 (d, J = 8.8 Hz, 1H, NH), 6.27 (s, 1H, H10), 6.26 (dd, J = 9.2, 9.2 Hz, 1H, H13), 5.97 (dd, J = 8.8, 2.5 Hz, 1H, H3' ) , 5.68 (d, J = 7.1 Hz, 1H, H2I3) , 4.93 (m, 1H, H5), 4.92 (m, 1H, H2'), 4.39 (m, 1H, H7), 4.30 (d, J = 8.5 Hz, 1H, H20a) , 4.20 (d, J = 8.5 Hz, 1H, H2013) , 3.81 (d, J = 7.1 Hz, 1H, H3), 3.60 (d, J - 5 Hz, 1H, 2'OH), 2.48 (m, 1H, H6a) , 2.45 (br, 1H, 70H) , 2.39 (s, 3H, 4Ac), 2.30 (m, 2H, H14) , 2.24 (s, 3H, lOAc) , 1.83 (m, 1H, H6G) , 1.82 (br s, 3H, Mel8), 1.68 (s, 1H, 10H), 1.68 (s, 3H, Mel9), 1.24 (s, 3H, Mel7), 1.14 (s, 3H, Mel6). <br><br>
24 4 4 5E <br><br>
24 <br><br>
wherein Np^ is no <br><br>
Preparation of 3'-desphenyl-3'-(1-naphthyl) taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -4 5 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(l-naphthyl)azetidin-2-one (620 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 325 mg of a mixture containing (2'R,3'S)-2',7-(bis)triethylsilyl-3'-desphenyl-3'-(1-naphthyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 325 mg (0.287 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C was added 2.8 mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 260 mg of material which was purified by flash chromatography to give yjVr £'V > <br><br>
V C <br><br>
. 1 <br><br>
T-** i i ^ ^A';on J <br><br>
24 4 4 58 <br><br>
25 <br><br>
166 mg (64%) of 3'-(1-naphthyl) taxol, which was recrystallized from methanol/water. <br><br>
m.p. 164-165 °C;[a]25Na-52.6° (c 0.005, CHC13). <br><br>
1H NMR (CDCI3, 300 MHz) 5 8.11 (d, J = 7.1 Hz, 2H, benzoate ortho), 8.11 (m, 3H, aromatic), 7.91 (m, 3H, aromatic), 7.70 (m, 2H, aromatic), 7.63-7.46 (m, 7H, aromatic), 6.75 (d, J = 8.8 Hz, 1H, NH), 6.52 (dd, J = 8.8, 1.6 Hz, 1H, H3 ' ) , 6.27 (s, 1H, H10) , 6.27 (dd, J = 9.1, 9.1 Hz, 1H, H13) , 5.68 (d, J = 7.1 Hz, 1H, H2fi) , 4.85 (dd, J = 7.6, 2.2 Hz, 1H, H5) , .4.97 (dd, J = 1.6 Hz, 1H, H2'), 4.39 (m, 1H, H7) , 4.24 (d, J = 8.5 Hz, 1H, H20a) , 4.17 (d, J = 8.5 Hz, 1H, H20f3) , 3.80 (d, J = 7.1 Hz, 1H, H3) , 3.65 (br, 1H, 2'OH), 2.55 (m, 1H, H6a), 2.48 (br, 1H, 70H), 2.41 (s, 3H, 4 Ac) , 2.38 (m, 1H, H14) , 1.96 (s, 3H, lOAc), 1.86 (m, 1H, H6I3), 1.80 (br s, 3H, Mel8), 1.76 (s, 1H, 10H), 1.69 (s, 3H, Mel9), 1.28 (s, 3H, Mel7), 1.16 (s, 3H, Mel6). <br><br>
v <br><br>
O <br><br>
24445ft <br><br>
26 <br><br>
EXAMPLE 6 <br><br>
MbO <br><br>
OH <br><br>
Preparation of 3'-desphenyl-3'-(4-methoxyphenyl) <br><br>
taxol, <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(4-methoxyphenyl)azetidin-2-one (590 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 320 mg of a mixture containing (2'R,3'S)-27-(bis)triethylsilyl-3'-desphenyl-3'-(4-methoxyphenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 320 mg (0.288 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C was added 2.8 mL of 48% aqueous HF. The mixture was stirred ^^for <br><br>
\ r O \ <br><br>
•C' \\ <br><br>
' J/} kt. Of <br><br>
'\ <br><br>
•N <br><br>
' V * <br><br>
o <br><br>
24 4 <br><br>
27 <br><br>
3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 255 mg of material which was purified by flash chromatography to give 172 mg (68%) of 3'-desphenyl-3'-(4-methoxyphenyl) taxol, which was recrystallized from methanol/water. <br><br>
m.p. 174-176 °C;[a]25Na-48.86° (c 0.05, CHC13). <br><br>
1H NMR (CDCI3, 300 MHz) S 8.12 (d, J = 7.1 Hz, 2H, benzoate ortho) , 7.72 (m, 2H, aromatic), 7.59 (m, 1H, aromatic), 7.53-7.36 (m, 8H, aromatic), 6.96 (d, J ~ 8.8 Hz, 1H, NH), 6.90 (m, 2H, aromatic), 6.26 (s, 1H, H10) , 6.21 (dd, J = 9.3, 9.3 Hz, 1H, H13) , 5.70 (dd, J = 8.8, 2.7 Hz, 1H, H3 •) , 5.66 (d, J = 6.8 Hz, 1H, H2I3) , 4.93 (dd, J = 9.9, 2.2 Hz, 1H, H5) , 4.74 (dd, J = 5.5, 2.7 Hz, 1H, H2' ) , 4.39 (m, 1H, H7) , 4.29 (d, J = 8.8 Hz, 1H, H20a) , 4.18 (d, J = 8.8 Hz, 1H, H20G), 3.78 (d, J = 6.8 Hz, 1H, H3), 3.78 (s, 3H, ArOMe) . 3.67 (d, J = 5.5 Hz, 1H, 2'OH), 2.61 (m, 1H, H6a) , 2.50 (d, J = 4.4 Hz, 1H, 70H) , 2.37 (s, 3H, 4Ac), 2.31 (m, 2H, H14) , 2.22 (s, 3H, lOAc) , 1.84 (m, 1H, H6B) , 1.79 (br s, 3H, Mel8), 1.79 (s, 1H, IOH) , 1.67 (s, 3H, Mel9), 1.22 (s, 3H, Mel7), 1.13 (s, 3H, Mel6). <br><br>
■v <br><br>
24 4458 <br><br>
28 <br><br>
EXAMPLE 7 <br><br>
CI <br><br>
OH <br><br>
Preparation of 3'-desphenyl-3'-(4-chlorophenyl) taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 inL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(4-chlorophenyl)azetidin-2-one (595 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 320 mg of a mixture containing (2'R,3'S)-2*,7-(bis)triethylsilyl 3'-desphenyl-3'-(4-chlorophenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 320 mg (0.287 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C was added 2.8 mL of 48% aqueous HF. The mixture was stirred>\a£.:4K °C for <br><br>
: * <br><br>
\\ 1a ■ '■ <br><br>
Of! <br><br>
^ ">1992 *j} <br><br>
24 44 58 <br><br>
29 <br><br>
3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 255 mg of material which was purified by flash chromatography to give 158 mg (62%) of 3'-desphenyl-3'-(4-chlorophenyl) taxol, which was recrystallized from methanol/water. <br><br>
m <br><br>
.p. 173-175 °C;[a]25Na-50.8° (c 0.01, CHCI3) <br><br>
1H NMR (CDCI3, 300 MHz) S 8.13 (d, J = 7.1 Hz, 2H, benzoate ortho), 7.72 (d, J = 8.2 Hz, 2H, benzamide ortho), 7.65-7.35 (m, 10H, aromatic), 6.97 (d, J = 8.8 Hz, 1H, NH), 6.27 (s, 1H, H10) , 6.25 (dd, J = 8.3, 8.3 Hz, 1H, H13), 5.78 (dd, J = 8.8, 2.2 Hz, 1H, H3') , 5.67 (d, J = 7.1 Hz, 1H, H2I3) , 4.95 (dd, J = 8.8, 2.2 Hz, 1H, H5) , 4.77 (br s, 1H, H2'), 4.40 (m, 1H, H7), 4.31 (d, J = 8.2 Hz, 1H, H20a), 4.19 (d, J = 8.2 Hz, 1H, H20I3) , 3.80 (d, J = 7.1 Hz, 1H, H3), 3.61 (br s, 1H, 2*OH), 2.54 (m, 1H, H6a), 2.38 (s, 3H, 4Ac), 2.32 (m, 2H, H14), 2.24 (s, 3H, lOAc), 1.85 (m, 1H, H6fi), 1.80 (br s, 3H, Mel8) , 1.68 (s, 3H, Mel9), 1.23 (s, 3H, Mel7), 1.14 (s, 3H, Mel6). <br><br>
24 4458 <br><br>
Preparation of 3'-desphenyl-3'-(4-bromophenyl) taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution in nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(4-bromophenyl) azetidin-2-one (660 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 330 mg of a mixture containing (2'R,3'S)-2' ,7-(bis)triethylsilyl-3'-desphenyl-3'-(4-bromophenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 330 mg (0.284 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C was added 2.8 mL of 48% aqueous HF. The mixture was stirred afcr-JO. °C for 3 h, then at 25 °C for 13 h, and partitioned ^e"t'ft&en <br><br>
24 44 58 <br><br>
31 <br><br>
saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 265 mg of material which was purified by flash chromatography to give 186 mg (64%) of 3'-desphenyl-3'-(4-bromophenyl) taxol, which was recrystallized from methanol/water. <br><br>
m.p. 170-172 °C;[a]25Na-50.94° (c 0.01, CHCI3). <br><br>
■^H NMR (CDCI3, 300 MHz) S 8.12 (d, J = 7.2 Hz, 2H, benzoate ortho), 7.71 (m, 2H, aromatic), 7.61 (m, 1H, aromatic), 7.50-7.47 (m, 6H, aromatic), 7.38 (m, 3H, aromatic), 7.04 (d, J = 8.8 Hz, 1H, NH), 6.27 (s, 1H, H10), 6.23 (dd, J = 8.2, 8.2 Hz, 1H, H13), 5.75 (dd, J = 8.8, 2.2 Hz, 1H, H31), 5.66 (d, J » 7.1 Hz, 1H, H2fl), 4.94 (dd, J = 9.3, 1.7 Hz, 1H, H5), 4.75 (dd, J = 2.2 Hz, 1H, H2•), 4.38 (m, 1H, H7), <br><br>
4.29 (d, J = 8.2 Hz, 1H, H20a) , 4.18 (d, J = 8.2 Hz, 1H, H20I3), 3.79 (d, J = 7.1 Hz, 1H, H3), 3.7 (br, 1H, 2'OH), 2.53 (m, 1H, H6a), 2.38 (br, 1H, 70H), 2.37 (s, 3H, 4Ac) , <br><br>
2.30 (m, 2H, H14) , 2.23 (s, 3H, 10Ac), 1.87 (m, 1H, H6I3) , 1.80 (br s, 3H, Mel8), 1.80 (s, 1H, IOH), 1.67 (s, 3H, Mel9), 1.22 (s, 3H, Mel7), 1.13 (s, 3H, Mel6). <br><br>
£ /V <br><br>
•••V c\ <br><br>
» «1,\ V <br><br>
(I 1 $ J A «, c)l <br><br>
\.<i n-JJ <br><br>
'A ' ' <br><br>
. '** 1 \> r O, -• <br><br>
2 4 4 4 5 8 <br><br>
32 <br><br>
EXAMPLE 9 <br><br>
OH <br><br>
Preparation of 3'-desphenyl-3'-(3,4-methylene-dioxyphenyl) taxol. <br><br>
To a solution of 7-triethyTsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(3,4-methylenedioxyphenyl)azetidin-2-one (610 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 320 mg of a mixture containing (2 ' R, 3'S)-2',7-(bis)triethylsilyl-3 ' -desphenyl-3'-(3,4-methylenedioxyphenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 320 mg (0.284 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C wasfa^ed 2.8 <br><br>
,y <br><br>
A <br><br>
24 44 58 <br><br>
33 <br><br>
mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 113 mg of material which was purified by flash chromatography to give 165 mg (64%) of 3-desphenyl-3'-(3,4-methylenedioxyphenyl) taxol, which was recrystallized from methanol/water. <br><br>
m <br><br>
.p. 178-180 °C; [<x]25Na-46.6° (c 0.005, CHCI3) <br><br>
1H NMR (CDCI3, 300 MHz) S 8.14 (d, J = 7.2 Hz, 2H, benzoate ortho), 7.72 (m, 2H, aromatic), 7.15 (m, 1H, aromatic), 7.50 (m, 2H, aromatic), 7.38 (m,2H, aromatic), 7.0 (m, 1H, aromatic), 6.94 (m, 2H, aromatic), 6.88 (d, J = 9.1 Hz, 1H, NH), 6.83 (m, 1H, aromatic), 6.28 (s, 1H, H10), 6.23 (dd, J = 9.1, 9.1 Hz, 1H, H13), 5.97 (s, 2H, methylene), 5 . o9 (dd, J = 9.1, 2.5 Hz, 1H, H3' ) , 5.68 (d, J « 6.9 Hz, 1H, H2I3) , 4.95 (dd, J = 9.6, 2.2 Hz, 1H, H5), 4.72 (dd, J = 2.5 Hz, 1H, H2'), 4.41 (m, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20a), 4.20 (d, J = 8.4 Hz, 1H, H20B), 3.81 (d, J = 6.9 Hz, 1H, H3), 3.60 (br, 1H, 2'OH), 2.56 (m, 1H, H6a), 2.43 (d, J = 4.1 Hz, 1H, 70H) , 2.39 (s, 3H, 4Ac) , 2.31 (m, 2H, H14), 2.24 (s, 3H, lOAc), 1.88 (m, 1H, H6IB) , 1.82 (br s, 3H, Mel8), 1.69 (S, 1H, 10H) , 1.68 (s, 3H, Mel9), 1.24 (s, 3H, Mel7), 1.15 (s, 3H, Mel6). <br><br>
.•/" ^ o <br><br>
<<•> \, <br><br>
.**3 _ — ' <br><br>
1 ; r » <br><br>
24 44 58 <br><br>
34 <br><br>
OH <br><br>
Preparation of 3'-desphenyl-3'-(3,4-dimethoxy-phenyl) taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(3,4-dimethoxyphenyl)azetidin-2-one (630 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 hr before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 330 mg of a mixture containing (2'R,3'S)-2',7-(bis)triethylsilyl-3 desphenyl-3'-(3,4-dimethoxyphenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 330 mg (0.286 mmol) of the mixture obtained from the previous reaction in. .18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C. gist's a&ded 2.8 <br><br>
'' <br><br>
.■'•V <br><br>
' > <br><br>
: £ fv c <br><br>
24 4458 <br><br>
35 <br><br>
mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 260 mg of material which was purified by flash chromatography to give 175 mg (67%) of 3 *-desphenyl-3'-(3,4-dimethoxyphenyl) taxol, which was recrystallized from methanol/water. <br><br>
m <br><br>
.p. 165-167 °C; [cxJ25Na-42.0o (c 0.005, CHC13) . <br><br>
XH NMR (CDC13, 300 MHz) S 8.12 (d, J = 8.3 Hz, 2H, benzoate ortho), 7.73 (d, J = 8.2 Hz, 2H, benzamide ortho), 7.65-7.35 (m, 6H, aromatic), 7.1-7.0 (m, 2H, aromatic), 6.94 (d, J = 8.8 Hz, 1H, NH) , 6.88 (d, J = 8.3 Hz, 2H, aromatic), 6.27 (s, 1H, H10), 6.21 (dd, J = 9.3, 9.3 Hz, lh, H13) , 5.69 (m, 2H, H3, H2IB) , 4.94 (dd, Hz, J = 9.9, 2.2 Hz, 1H, H5), 4.77 (d, J = 2.8 Hz, 1H, H21 ) , 4.39 (dd, J = 11.0, 6.6 Hz, 1H, H7), 4.30 (d, J = 8.5 Hz, 1H, H20a), 4.19 (d, J = 8.5 Hz, 1H, H20I3), 3.88 (s, 3H, ArOtle) , 3.87 (s, 3H, ArOMe), 3.80 (d, J = 7.1 Hz, 1H, H3), 3.59 (d, J = 4.4 Hz, 1H, 2'OH), 2.54 (m, 1H, H6a), 2.38 (s, 3H, 4Ac), 2.36 (m, 2H, H14a, H14I3) , 2.23 (s, 3H, lOAc) , 1.86 (m, 1H, H6B) , 1.80 (br s, 3H, Mel8), 1.68 (s, 3H, Mel9) , 1.23 (s, 3H, Mel7), 1.14 (s, 3H, Mel6). <br><br>
24 4 4 5 0i <br><br>
36 <br><br>
EXAMPLE 11 <br><br>
O Ph O <br><br>
OAc <br><br>
AAA /= <br><br>
EtO N oiiii'"' <br><br>
H OH <br><br>
OH <br><br>
Preparation of N-debenzoyl-N-ethoxycarbonyl taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (155 mg, 0.221 mmol) in 2 mL of THF at -45 °C was added dropwise 0.136 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-ethoxycarbonyl-3-triethylsilyloxy-4-phenylazetidin-2-one (386 mg, 1.11 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 252 mg of a mixture containing (2'R,3'S)-2',7-(bis)triethylsilyl-N-debenzoyl-N-ethoxycarbonyl taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 252 mg (0.112 mmol) of the mixture obtained from the previous reaction in 12 mL of acetonitrile and 0.6 mL of pyridine at 0 °C was added 1.8 mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between <br><br>
7 ' <br><br>
>\ 18 J'^l993 £/ <br><br>
A • J <br><br>
s,-.p;v£. <br><br>
24 4 4 58 <br><br>
37 <br><br>
saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 216 mg of material which was purified by flash chromatography to give 155 mg (85%) of N-debenzoyl-N-ethoxycarbonyl taxol, which was recrystallized from methanol/water. <br><br>
m.p. 161.5-162.5 °C; [a]25Na-62 .2° (c 0.51, CHCI3) . <br><br>
ifi NMR (CDC13, 300 MHz) S 8.12 (d, J = 7.7 Hz, 2H, benzoate ortho), 7.65-7.3 (m, 8H, aromatic), 6.28 (m, 1H, H10) 6.27(m, 1H, H13) , 5.67 (d, J = 7.1 Hz, 1H, H2I3), 5.53 (d, J = 9.3 Hz, 1H, H3'), 5.29 (d, J = 9.3 Hz, 1H, NH), 4.94 (dd, J = 9.3, 2.2 Hz, 1H, H5) , 4.64 (dd, J = 5.0, 2.8 Hz, 1H, H2' ) , 4.41 (m, 1H, H7), 4.29 (d, J = 8.5 Hz, 1H, H20a), 4.17 (d, J = 8.5 Hz, 1H, H20B) , 4.01 (q, J = 7.1 Hz, 2H, COO£H2CH3), 3.79 (d, J = 7.1 Hz, 1H, H3), 3.45 (d, J = 5 Hz, 1H, 2'OH) , 2.54 (m, 1H, H6a) , 2.47 (d, J = 3.9 Hz 1H, 70H) , 2.36 (s, 3H, 4Ac),2.24 (s, 3H, lOAc) , 2.22 (m, 2H, H14a, H14B), 1.87 (m, 1H, H6a), 1.83 (br s, 3H, Mel8), 1.77 (s, 1H, 10H), 1.68 (s, 3H, Mel9), 1.27 (s, 3H, Mel7) , 1.15 (s, 3H, Mel6), 1.14 (t, J = 7.1 Hz, 2H, COOCH2£H3) . <br><br>
. ' x O -\ <br><br>
i;M <br><br>
t *V> \\ <br><br>
24 4 4 <br><br>
38 <br><br>
EXAMPLE 12 <br><br>
Preparation of 3'-desphenyl-3*-(4-nitrophenyl) <br><br>
taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(4-nitrophenyl)azetidin-2-one (610 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 320 mg of a mixture containing (2'R,3'S)-2 ' ,7-(bis)triethylsilyl-3'-desphenyl-3'-(4-nitrophenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 320 mg (0.284 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C was added 2.8 mL of 48% aqueous HF. The mixtur^was" 's£rirred at 0 °C for <br><br>
Ojj f 8 J A N tianv uyj o <br><br>
: • r t M o sy*' <br><br>
a // <br><br>
14 4458 <br><br>
39 <br><br>
3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 255 mg of material which was purified by flash chromatography to give 147 mg (57%) of 3'-desphenyl-3'-(4-nitrophenyl) taxol, which was recrystallized from methanol/water. <br><br>
m.p. 188-190 °C; [<x]25Na-63.7° (c 0.01, CHC13) . <br><br>
1H NMR (CDC13, 300 MHz) 5 8.26 (d, J = 8.8 Hz, 2H, benzoate ortho), 8.20 (m, 2H, aromatic), 7.73 (m, 4H, aromatic), 7.60 (m, 1H, aromatic), 7.52 (m, 4H, aromatic), 7.41 (m, 1H, aromatic), 7.15 (d, J = 8.8 Hz, 1H, NH), 6.26 (s, 1H, H10) , 6.26 (dd, J = 9.3, 9.3 Hz, 1H, H13), 5.93 (dd, J = 8.8, 2.8 Hz, 1H, H3') , 5.66 (d, J = 6.6 Hz, 1H, H2I3), 4.94 (dd, J = 9.3, 1.7 Hz, 1H, H5), 4.82 (dd, J = 3.9, 2.8 Hz, 1H, H2'), 4.38 (m, 1H, H7), 4.30 (d, J = 8.8 Hz, 1H, H20a), 4.19 (d, J = 8.8 Hz, 1H, H20I3) , 3.86 (d, J = 3.9 Hz, 1H, 2 ' OH) , 3.79 (d, J = 6.6 Hz, 1H, H3), 2.55 (m, 1H, H6a), 2.46 (d, J = 3.8 Hz, 1H, 70H), 2.41 (s, 3H, 4Ac) , 2.38 (m, 2H, H14) , 2.23 (s, 3H, lOAc) , 1.82 (m, 1H, H6B) , 1.80 (br s, 3H, Mel8), 1.74 (s, 1H, 10H) , 1.68 (s, 3H, Mel9), 1.21 (s, 3H, Me17), 1.13 (s, 3H, Mel6). <br><br>
40 <br><br>
EXAMPLE 13 <br><br>
24 44 58 <br><br>
o o <br><br>
OAc <br><br>
XXX x <br><br>
N =■ O'iniik <br><br>
Ph N <br><br>
H OH <br><br>
C4) <br><br>
Preparation of N-debenzoyl-N-methoxycarbonyl taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (100 mg, 0.143 mmol) in 1 mL of THF at - 45°C was added dropwise 0.087 mL of a 163M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-methoxycarbonyl-3-triethylsilyloxy-4-phenylazetidin-2-one (252 mg, 0.715 mmol) in 1 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between • saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 129 mg of a mixture containing (2 *R,3'S)-2',7-(bis)triethylsilyl-N-debenzoyl-N-methoxycarbonyl taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 129 mg (0.112 mmol) of the mixture obtained from the previous reaction in 6 mL of acetonitrile and 0.3 mL of pyridine at 0 rXd--was added 0.9 <br><br>
\ 8 jA^i99^ £f <br><br>
// <br><br>
4 4 4 5 8; <br><br>
41 <br><br>
mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 108 mg of material which was purified by flash chromatography to give 90 mg (76%) of N-debenzoyl-N-methoxycarbonyl taxol, which was recrystallized from methanol/water. <br><br>
m <br><br>
.p. 169-171 °C; [a]25Na-63.7° (c 1.1, CHC13). <br><br>
1H NMR (CDC13, 300 MHz) S 8.12 (d, J = 7.1 Hz, 2H, benzoate ortho), 7.65-7.3 (m, 8H, aromatic), 6.28 (m, 2H, H10, H13), 5.66 (d, J = 7.1 Hz, 1H, H213) , 5.58 (d, J = 9.4 Hz, 1H, H3'), 5.30 (d, J = 9.4 Hz, 1H, NH), 4.93 (dd, J = 9.3, 1.7 Hz, 1H, H5), 4.65 (br s, 1H, H2'), 4.40 (m, 1H, H7), 4.29 (d, J = 8.8 Hz, 1H, H20a) , 4.17 (d, J = 8.8 Hz, 1H, H20I3) , 3.79 (d, J = 7.1 Hz, 1H, H3), 3.58 (s, 3H, COOMfi), 3.34 (d, J = 5 Hz, 1H, 2'OH), 2.54 (m, 1H, H6a), 2.47 (d, J = 3.8 Hz 1H, 7 OH) , 2.36 (s, 3H, 4Ac),2.24 (s, 3H, lOAc) , 2.22 (m, 2H, H14a, H1413) , 1.88 (m, 1H, H6a) , 1.82 (br s, 3H, Mel8) , 1.73 (s, 1H, IOH), 1.68 (s, 3H, Mel9), 1.27 (s, 3H, Mel7), 1.14 (s, 3H, Mel6). <br><br>
% o , <br><br>
t, f +C <br><br>
•\ 18 y <br><br>
, f? r + f <br><br>
24 4 4 58 <br><br>
42 <br><br>
EXAMPLE 14 <br><br>
Preparation of 3'-desphenyl-3(4-fluorophenyl) <br><br>
taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (200 mg, 0.286 mmol) in 2 mL of THF at -45 °C was added dropwise 0.174 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-benzoyl-3-tri-ethylsilyloxy-4-(4-fluorophenyl)azetidin-2-one (570 mg, 1.43 mmol) in 2 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHC03 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 315 mg of a mixture containing (2*R,3'S)-2',7-(bis)triethylsilyl-3'-desphenyl-3'-(4-fluorophenyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 315 mg (0.286 mmol) of the mixture obtained from the previous reaction in 18 mL of acetonitrile and 0.93 mL of pyridine at 0 °C.was added 2.8 <br><br>
O v <br><br>
/ <br><br>
J . g <br><br>
A T'/J <br><br>
// <br><br>
•tj „ O />v <br><br>
' •r * v <br><br>
4 4458 <br><br>
43 <br><br>
mL of 48% aqueous HF. The mixture was stirred at 0 °C for 3 h, then at 25 °C for 13 h, and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 250 mg of material which was purified by flash chromatography to give 160 mg (64%) of 3'-desphenyl-3'-(4-fluorophenyl) taxol, which was recrystallized from methanol/water. <br><br>
m.p.171-173 °C;[a]25Na-49.0° (c 0.005, CHCI3). <br><br>
1H NMR (CDCI3, 300 MHz) 6 8.13 (d, J = 7.5 Hz, 2H, benzoate ortho), 7.25 (m, 2H, aromatic), 7.61 (m, 1H, aromatic), 7.50 (m, 4H, aromatic), 7.43 (m, 2H, aromatic), 7.10 (m, 2H, aromatic), 6.96 (d, J = 8.7 Hz, 1H, NH), 6.27 (s, 1H, H10) , 6.25 (dd, J = 8.7, 8.7 Hz, 1H, H13), 5.79 (dd, J = 8.7, 2.4 Hz, 1H, H3 ' ) , 5.67 (d, J = 7.1 Hz, 1H, H2I3) , 4.45 (dd, J = 7.9 Hz, 1H, H5), 4.76 (dd, J = 4.8, 2.4 Hz, 1H, H21 ) , 4.39 (m, 1H, H7) , 4.31 (d, J = 8.9 Hz, 1H, H20a) , 4.20 (d, J = 8.9 Hz, 1H, H20I3), 3.80 (d, J = 7.1 Hz, 1H, H3), 3.57 (d, J = 4.8 Hz, 1H, 2'OH), 2.58 (m, 1H, H6a) , 2.43 (d, J = 4.3 Hz, 1H, 70H), 2.38 (s, 3H, 4Ac), 2.30 (m, 2H, H14), 2.24 (s, 3H, lOAc), 1.85 (m, 1H, H6I3), 1.80 (br s, 3H, Mel8), 1.69 (s, 1H, 10H) , 1.55 (s, 3H, Mel9), 1.23 (s, 3H, Mel7), 1.14 (s, 3H, Mel6). <br><br>
*0 \ f <br><br>
\V <br><br>
1 o ' <br><br>
•\ ?•/ <br><br>
44 <br><br>
EXAMPLE 15 <br><br>
4 4 4 58' <br><br>
o ^ o <br><br>
OAC <br><br>
I § H OH <br><br>
C5) <br><br>
Preparation of 3'-Desphenyl-3(2-thienyl) taxol. <br><br>
To a solution of 7-triethylsilyl baccatin III (100 mg, 0.143 mmol) in 1 mL of THF at -45 °C was added dropwise 0.087 mL of a 1.63M solution of nBuLi in hexane. After 0.5 h at -45 °C, a solution of cis-l-(4-benzoyl)-3-triethylsilyloxy-4-(2-thienyl)azetidin-2-one (277 mg, 0.715 mmol) in 1 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 1 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHCC>3 and 60/40 ethyl acetate/hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 169 mg of a mixture containing (2'R,3'S)-2',7-(bis)triethylsilyl-3'-desphenyl-3'-(2-thienyl) taxol and a small amount of the (2'S,3'R) isomer. <br><br>
To a solution of 169 mg of the mixture obtained from the previous reaction in 6 mL of acetonitrile and 0.3 mL of pyridine at 0 °C was added 0.9 mL of 48% aqueous HF. <br><br>
I <br><br>
• 13 jAKI99$ <br><br>
^ - // <br><br></p>
</div>
Claims (6)
1. A metal alkoxide having the following formula:<br><br> z wherein is hydrogen or a hydroxy protecting group, Z is -0T2, or -OCOCH3, T2 is hydrogen or a hydroxy protecting group, M is a metal, Ac is acetyl and Ph is phenyl.<br><br>
2. The metal alkoxide of claim 1 wherein M is Li, Mg, Na, K or Ti.<br><br>
3. The metal alkoxide of claim 1 wherein M is lithium.<br><br>
4. The metal alkoxide of claim 1 wherein M is lithium, Z is -OT2, and T2 is a hydroxy protecting group.<br><br>
5. The metal alkoxide of claim 4 wherein Tj and T2 are independently selected from the group consisting of 1-ethoxyethyl, 2,2,2-trichloroethoxymethyl, trialkyl silyl and triaryl silyl.<br><br>
6. A metal alkoxide according to any one of claims 1 to 5<br><br> </p> </div>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76380591A | 1991-09-23 | 1991-09-23 | |
US07/862,778 US5229526A (en) | 1991-09-23 | 1992-04-03 | Metal alkoxides |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ244458A true NZ244458A (en) | 1994-06-27 |
Family
ID=27117339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ244458A NZ244458A (en) | 1991-09-23 | 1992-09-23 | Metal alkoxides of taxane derivatives |
Country Status (24)
Country | Link |
---|---|
US (1) | US5229526A (en) |
EP (1) | EP0605638B1 (en) |
JP (1) | JP3320416B2 (en) |
CN (1) | CN1058714C (en) |
AT (1) | ATE184004T1 (en) |
AU (1) | AU643911B2 (en) |
CA (1) | CA2098568C (en) |
CZ (1) | CZ289299B6 (en) |
DE (1) | DE69229916T2 (en) |
DK (1) | DK0605638T3 (en) |
ES (1) | ES2137951T3 (en) |
FI (1) | FI109796B (en) |
HU (1) | HU225914B1 (en) |
IL (1) | IL103192A (en) |
MX (1) | MX9205370A (en) |
MY (1) | MY128481A (en) |
NO (1) | NO305120B1 (en) |
NZ (1) | NZ244458A (en) |
PH (1) | PH30213A (en) |
PT (1) | PT100884B (en) |
RU (1) | RU2098413C1 (en) |
TW (1) | TW368502B (en) |
UA (1) | UA41287C2 (en) |
WO (1) | WO1993006094A1 (en) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721268A (en) * | 1991-09-23 | 1998-02-24 | Florida State University | C7 taxane derivatives and pharmaceutical compositions containing them |
US6794523B2 (en) | 1991-09-23 | 2004-09-21 | Florida State University | Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them |
US5284864A (en) * | 1991-09-23 | 1994-02-08 | Florida State University | Butenyl substituted taxanes and pharmaceutical compositions containing them |
US5430160A (en) * | 1991-09-23 | 1995-07-04 | Florida State University | Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides |
US6028205A (en) * | 1991-09-23 | 2000-02-22 | Florida State University | C2 tricyclic taxanes |
US6005138A (en) | 1991-09-23 | 1999-12-21 | Florida State University | Tricyclic taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them |
US5728725A (en) * | 1991-09-23 | 1998-03-17 | Florida State University | C2 taxane derivaties and pharmaceutical compositions containing them |
US6495704B1 (en) | 1991-09-23 | 2002-12-17 | Florida State University | 9-desoxotaxanes and process for the preparation of 9-desoxotaxanes |
US5714513A (en) * | 1991-09-23 | 1998-02-03 | Florida State University | C10 taxane derivatives and pharmaceutical compositions |
US6018073A (en) * | 1991-09-23 | 2000-01-25 | Florida State University | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them |
US6335362B1 (en) | 1991-09-23 | 2002-01-01 | Florida State University | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them |
US6521660B2 (en) | 1991-09-23 | 2003-02-18 | Florida State University | 3′-alkyl substituted taxanes and pharmaceutical compositions containing them |
US5728850A (en) * | 1991-09-23 | 1998-03-17 | Florida State University | Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them |
US5710287A (en) | 1991-09-23 | 1998-01-20 | Florida State University | Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them |
ZA926827B (en) * | 1991-09-23 | 1993-03-15 | Univ Florida State | Novel furyl and thienyl substituted taxanes and pharmaceutical compositions containing them. |
US5998656A (en) * | 1991-09-23 | 1999-12-07 | Florida State University | C10 tricyclic taxanes |
US7074945B2 (en) * | 1991-09-23 | 2006-07-11 | Florida State University | Metal alkoxide taxane derivatives |
US6011056A (en) * | 1991-09-23 | 2000-01-04 | Florida State University | C9 taxane derivatives and pharmaceutical compositions containing them |
US5739362A (en) * | 1991-09-23 | 1998-04-14 | Florida State University | Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them |
US5489601A (en) * | 1991-09-23 | 1996-02-06 | Florida State University | Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them |
US5294637A (en) * | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
FR2698363B1 (en) * | 1992-11-23 | 1994-12-30 | Rhone Poulenc Rorer Sa | New taxane derivatives, their preparation and the compositions containing them. |
US5380751A (en) * | 1992-12-04 | 1995-01-10 | Bristol-Myers Squibb Company | 6,7-modified paclitaxels |
FR2698871B1 (en) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | New taxoids, their preparation and the pharmaceutical compositions containing them. |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
DK0679156T3 (en) * | 1993-01-15 | 2000-09-04 | Univ Florida State | Process for the preparation of 10-desacetoxybaccatin III and 10-desacetoxytaxol and derivatives thereof |
ZA94128B (en) * | 1993-02-01 | 1994-08-19 | Univ New York State Res Found | Process for the preparation of taxane derivatives and betalactam intermediates therefor |
US6187916B1 (en) * | 1993-02-01 | 2001-02-13 | Research Foundation Of State University Of New York | Process for the preparation of taxane derivatives and β-lactam intermediates therefor |
US6593482B2 (en) | 1993-02-01 | 2003-07-15 | Aventis Pharma S.A. | Methods for preparing new taxoids and pharmaceutical compositions containing them |
US6710191B2 (en) | 1993-03-05 | 2004-03-23 | Florida State University | 9β-hydroxytetracyclic taxanes |
US6066747A (en) * | 1993-03-05 | 2000-05-23 | Florida State University | Process for the preparation of 9-desoxotaxanes |
US5547981A (en) * | 1993-03-09 | 1996-08-20 | Enzon, Inc. | Taxol-7-carbazates |
TW467896B (en) | 1993-03-19 | 2001-12-11 | Bristol Myers Squibb Co | Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes |
WO1994021252A1 (en) * | 1993-03-22 | 1994-09-29 | Florida State University | Taxanes having a pyridyl substituted side-chain |
EP1260223B1 (en) * | 1993-03-22 | 2005-05-11 | Florida State University | Taxanes having furyl or thienyl substituted side-chain |
FR2703049B1 (en) | 1993-03-22 | 1995-04-21 | Rhone Poulenc Rorer Sa | Method for the purification of taxoids. |
IT1261667B (en) * | 1993-05-20 | 1996-05-29 | TAX FOR ANTI-CANCER ACTIVITIES. | |
AU693797B2 (en) * | 1993-07-19 | 1998-07-09 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
US5405972A (en) * | 1993-07-20 | 1995-04-11 | Florida State University | Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes |
US6005120A (en) | 1993-07-20 | 1999-12-21 | Florida State University | Tricyclic and tetracyclic taxanes |
CA2129288C (en) * | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
JPH09504033A (en) * | 1993-10-20 | 1997-04-22 | エンゾン,インコーポレーテッド | 2'- and / or 7-substituted taxoids |
US6441026B1 (en) | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
FR2718137B1 (en) * | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Process for the preparation of trialcoylsilyl-7 baccatine III. |
FR2722191B1 (en) * | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE |
US6201140B1 (en) | 1994-07-28 | 2001-03-13 | Bristol-Myers Squibb Company | 7-0-ethers of taxane derivatives |
US6458976B1 (en) | 1994-10-28 | 2002-10-01 | The Research Foundation Of State University Of New York | Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods |
US6100411A (en) * | 1994-10-28 | 2000-08-08 | The Research Foundation Of State University Of New York | Taxoid anti-tumor agents and pharmaceutical compositions thereof |
AU4133096A (en) * | 1994-10-28 | 1996-05-23 | Research Foundation Of The State University Of New York, The | Taxoid derivatives, their preparation and their use as antitumor agents |
US6500858B2 (en) | 1994-10-28 | 2002-12-31 | The Research Foundation Of The State University Of New York | Taxoid anti-tumor agents and pharmaceutical compositions thereof |
US5847170A (en) * | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
MA23823A1 (en) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | NEW TAXOIDS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
US5760251A (en) * | 1995-08-11 | 1998-06-02 | Sepracor, Inc. | Taxol process and compounds |
JP2001524067A (en) * | 1995-09-13 | 2001-11-27 | フロリダ・ステイト・ユニバーシティ | Radiation sensitizing taxanes and their pharmaceutical preparations |
US6177456B1 (en) | 1995-10-02 | 2001-01-23 | Xechem International, Inc. | Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor |
US5854278A (en) * | 1995-12-13 | 1998-12-29 | Xechem International, Inc. | Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents |
US5807888A (en) * | 1995-12-13 | 1998-09-15 | Xechem International, Inc. | Preparation of brominated paclitaxel analogues and their use as effective antitumor agents |
US5654448A (en) * | 1995-10-02 | 1997-08-05 | Xechem International, Inc. | Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes |
US5840748A (en) * | 1995-10-02 | 1998-11-24 | Xechem International, Inc. | Dihalocephalomannine and methods of use therefor |
CA2253513A1 (en) * | 1996-05-06 | 1997-11-13 | Florida State University | 1-deoxy baccatin iii, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof |
US5635531A (en) * | 1996-07-08 | 1997-06-03 | Bristol-Myers Squibb Company | 3'-aminocarbonyloxy paclitaxels |
US5750736A (en) * | 1996-07-11 | 1998-05-12 | Napro Biotherapeutics, Inc. | Method for acylating 10-deacetylbaccatin III selectively at the c-10 position |
US5750737A (en) * | 1996-09-25 | 1998-05-12 | Sisti; Nicholas J. | Method for paclitaxel synthesis |
US5973170A (en) * | 1996-09-25 | 1999-10-26 | Napro Biotherapuetics, Inc. | C-7 metal alkoxides of baccatin III |
US5912264A (en) * | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
US6017935A (en) * | 1997-04-24 | 2000-01-25 | Bristol-Myers Squibb Company | 7-sulfur substituted paclitaxels |
US7288665B1 (en) * | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
US5917062A (en) * | 1997-11-21 | 1999-06-29 | Indena S.P.A | Intermediates and methods useful in the semisynthesis of paclitaxel and analogs |
US5914411A (en) * | 1998-01-21 | 1999-06-22 | Napro Biotherapeutics, Inc. | Alternate method for acylating 10-deacetylbaccatin III selectively at the C-10 position |
US6156789A (en) * | 1998-03-17 | 2000-12-05 | Rhone-Poulenc Rorer S.A. | Method for treating abnormal cell proliferation in the brain |
US6048990A (en) * | 1998-05-01 | 2000-04-11 | Napro Biotherapeutics, Inc. | Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position |
US6066749A (en) * | 1998-05-01 | 2000-05-23 | Napro Biotherapeutics, Inc. | Method for conversion of C-2'-O-protected-10-hydroxy taxol to c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis |
ES2230849T3 (en) | 1998-05-01 | 2005-05-01 | Tapestry Pharmaceuticals, Inc. | USEFUL PROCEDURES AND INTERMEDIARIES FOR THE SYNTHESIS OF PACLITAXEL FROM C-7, C-10 DI-CBZ BACATINA III. |
US6025516A (en) * | 1998-10-14 | 2000-02-15 | Chiragene, Inc. | Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes |
US6136999A (en) * | 1999-06-21 | 2000-10-24 | Napro Biotherapeutics, Inc. | C-2 hydroxyl protected-n-acyl (2R,3S)-3-phenylisoserine substituted phenyl activated esters and method for production thereof |
US6143902A (en) * | 1999-06-21 | 2000-11-07 | Napro Biotherapeutics, Inc. | C-2 hydroxyl protected-N-acyl (2R,3S)-3-phenylisoserine N-imido activated esters and method for production thereof |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6548293B1 (en) | 1999-10-18 | 2003-04-15 | Fsu Research Foundation, Inc. | Enzymatic process for the resolution of enantiomeric mixtures of β-lactams |
US7063977B2 (en) * | 2001-08-21 | 2006-06-20 | Bristol-Myers Squibb Company | Enzymatic resolution of t-butyl taxane derivatives |
WO2003047508A2 (en) * | 2001-11-30 | 2003-06-12 | Bristol-Myers Squibb Company | Paclitaxel solvates |
US6703599B1 (en) * | 2002-01-30 | 2004-03-09 | Microsoft Corporation | Proximity sensor with adaptive threshold |
US20040132991A1 (en) * | 2002-10-09 | 2004-07-08 | Phytogen Life Sciences Inc. | Novel taxanes and methods related to use and preparation thereof |
US7030253B2 (en) * | 2003-08-07 | 2006-04-18 | Bristol-Myers Squibb Company | Process for preparing 4-alkyl- or 4-aryl-oxycarbonyl paclitaxel analogs and novel intermediates |
US7202370B2 (en) * | 2003-10-27 | 2007-04-10 | Conor Medsystems, Inc. | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III |
US20050272807A1 (en) * | 2004-06-04 | 2005-12-08 | Phytogen Life Sciences Inc. | Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel |
US20050288520A1 (en) * | 2004-06-25 | 2005-12-29 | Phytogen Life Sciences Inc. | One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel |
JP2006302679A (en) * | 2005-04-21 | 2006-11-02 | Seiko Epson Corp | Formation method of conductive film and manufacturing method of electronic apparatus |
WO2006116532A2 (en) * | 2005-04-28 | 2006-11-02 | University Of Massachusetts Lowell | Synthesis of oligo/poly(catechins) and methods of use |
WO2008051465A2 (en) * | 2006-10-20 | 2008-05-02 | Scinopharm Singapore Pte, Ltd. | Process for making crystalline anhydrous docetaxel |
CN101289432B (en) * | 2007-04-20 | 2010-12-15 | 上海天伟生物制药有限公司 | Novel isoserine ester derivates and method for preparing same |
WO2009137084A2 (en) * | 2008-05-07 | 2009-11-12 | Ivax Research, Llc | Processes for preparation of taxanes and intermediates thereof |
KR101096282B1 (en) | 2009-04-24 | 2011-12-20 | 주식회사 삼양제넥스 | Method for Preparing Taxane Derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2601676B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF TAXOL AND DESACETYL-10 TAXOL |
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
FR2629818B1 (en) * | 1988-04-06 | 1990-11-16 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF TAXOL |
FR2629819B1 (en) * | 1988-04-06 | 1990-11-16 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF BACCATIN III AND DESACETYL-10 BACCATIN III DERIVATIVES |
US5015744A (en) * | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
-
1992
- 1992-04-03 US US07/862,778 patent/US5229526A/en not_active Expired - Lifetime
- 1992-09-16 IL IL103192A patent/IL103192A/en not_active IP Right Cessation
- 1992-09-21 MY MYPI92001683A patent/MY128481A/en unknown
- 1992-09-21 PH PH44959A patent/PH30213A/en unknown
- 1992-09-21 PT PT100884A patent/PT100884B/en active IP Right Grant
- 1992-09-22 ES ES92921317T patent/ES2137951T3/en not_active Expired - Lifetime
- 1992-09-22 AT AT92921317T patent/ATE184004T1/en not_active IP Right Cessation
- 1992-09-22 CA CA002098568A patent/CA2098568C/en not_active Expired - Fee Related
- 1992-09-22 EP EP92921317A patent/EP0605638B1/en not_active Expired - Lifetime
- 1992-09-22 MX MX9205370A patent/MX9205370A/en not_active IP Right Cessation
- 1992-09-22 JP JP50627793A patent/JP3320416B2/en not_active Expired - Fee Related
- 1992-09-22 WO PCT/US1992/007952 patent/WO1993006094A1/en active IP Right Grant
- 1992-09-22 HU HU9400831A patent/HU225914B1/en not_active IP Right Cessation
- 1992-09-22 DE DE69229916T patent/DE69229916T2/en not_active Expired - Fee Related
- 1992-09-22 DK DK92921317T patent/DK0605638T3/en active
- 1992-09-22 AU AU26888/92A patent/AU643911B2/en not_active Ceased
- 1992-09-22 UA UA94005359A patent/UA41287C2/en unknown
- 1992-09-22 CZ CZ1994662A patent/CZ289299B6/en not_active IP Right Cessation
- 1992-09-22 RU RU9494019168A patent/RU2098413C1/en not_active IP Right Cessation
- 1992-09-23 CN CN92112482A patent/CN1058714C/en not_active Expired - Fee Related
- 1992-09-23 NZ NZ244458A patent/NZ244458A/en not_active IP Right Cessation
- 1992-10-21 TW TW081108376A patent/TW368502B/en not_active IP Right Cessation
-
1994
- 1994-03-22 NO NO941020A patent/NO305120B1/en not_active IP Right Cessation
- 1994-03-22 FI FI941323A patent/FI109796B/en active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5229526A (en) | Metal alkoxides | |
US5274124A (en) | Metal alkoxides | |
US5723634A (en) | Metal alkoxide compounds | |
US5254703A (en) | Semi-synthesis of taxane derivatives using metal alkoxides and oxazinones | |
CA2098478C (en) | Preparation of substituted isoserine esters using metal alkoxides and .beta.-lactams | |
IE74154B1 (en) | Method for preparation of taxol using an oxazinone | |
US7074945B2 (en) | Metal alkoxide taxane derivatives | |
AU647971C (en) | Preparation of isoserine ester and taxane | |
PT100883B (en) | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES USING METALIC AND B-LACTAMAN ALCOXIDES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
EXPY | Patent expired |